Exhibit 10.10
NexImmune, Inc.
Non-Employee Director Compensation Policy
The Board of Directors of NexImmune, Inc. (the “Company”) has approved the following Non-Employee Director Compensation Policy (this “Policy”) which establishes compensation to be paid to non-employee directors of the Company, effective as of the closing of the Company’s initial public offering of common stock (the “Effective Time”), to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company’s Board of Directors (the “Board”).
Applicable Persons
This Policy shall apply to each director of the Company who is not an employee of, or consultant to, the Company or any Affiliate (each, an “Outside Director”). “Affiliate” shall mean a corporation which is a direct or indirect parent or subsidiary of the Company, as determined pursuant to Section 424 of the Internal Revenue Code of 1986, as amended.
Stock Option Grants
All stock option grant amounts set forth herein shall be subject to automatic adjustment in the event of any stock split or other recapitalization affecting the Company’s common stock.
Annual Stock Option Grants
Commencing in calendar year 2022, each Outside Director shall be granted options to purchase the following shares of the Company’s common stock (the “Annual Stock Option Grant”) under the Company’s 2021 Equity Incentive Plan (the “Stock Plan”) each year on or about the time of the annual meeting of the Board of Directors following the Company’s annual meeting of stockholders:
| | |
Outside Director | | Stock Options |
Outside Director serving as Chairman of the Board | | 330,000 |
Other Outside Director | | 165,000 |
If there has been no annual meeting of stockholders held by the first day of the third fiscal quarter, each Outside Director will still receive any annual stock option grants provided for under this Policy on the first day of the third fiscal quarter of such year. The exercise price of the options to be granted to each Outside Director as their Annual Stock Option Grant shall be the fair market value of the Company’s common stock as of the grant date, which shall be deemed to be the closing price on such date of the Company’s common stock on a national securities exchange.